Sign In
Buy HRMY
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
PLYMOUTH MEETING, Pa. , June 5, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepin
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE
08:05am, Tuesday, 28'th May 2024
PLYMOUTH MEETING, Pa. , May 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcomi
Amalgamated Bank Lowers Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
05:01am, Monday, 20'th May 2024
Amalgamated Bank lessened its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 8.1% in the fourth quarter, according to the company in its most recent filing with th
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
01:46pm, Wednesday, 01'st May 2024
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
HRMY or TECH: Which Is the Better Value Stock Right Now?
12:41pm, Wednesday, 01'st May 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks offers value invest
Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript
01:49pm, Tuesday, 30'th Apr 2024
Harmony Biosciences Holdings, Inc (NASDAQ:HRMY ) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET Company Participants Luis Sanay - Head of Investor Relations Jeffrey Dayno - President & Chi
WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half
Lead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026 Plan to Initiate Phase 3 T
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
08:05am, Tuesday, 16'th Apr 2024
PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30,
PLYMOUTH MEETING, Pa. , April 11, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and com
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
08:05am, Wednesday, 03'rd Apr 2024
PLYMOUTH MEETING, Pa. , April 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to evaluate
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
08:05am, Tuesday, 26'th Mar 2024
PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upco
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
08:05am, Wednesday, 28'th Feb 2024
PLYMOUTH MEETING, Pa. , Feb. 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming inve
HRMY vs. TECH: Which Stock Is the Better Value Option?
12:41pm, Friday, 23'rd Feb 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stoc
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
09:45am, Thursday, 22'nd Feb 2024
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $1.01 per share a y
